Extended Follow-up of Autologous Bone Marrow Transplantation with 4-Hydroperoxycyclophosphamide (4-HC) Purging for Indolent or Transformed Non-Hodgkin Lymphomas

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 3, 2011, Pages 365-373

  Kasamon, Yvette L ^a   Jones, Richard J ^a   Gocke, Christopher D ^a   Blackford, Amanda L ^a   Seifter, Eric J ^a   Davis Sproul, Janice M ^a   Gore, Steven D ^a   Ambinder, Richard F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

4 Hydroperoxycyclophosphamide (4 HC); Autologous transplantation; Lymphoma; Purging

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; BUSULFAN; CYCLOPHOSPHAMIDE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW PURGING; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC LYMPHATIC LEUKEMIA; DISEASE SEVERITY; EVENT FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GUILLAIN BARRE SYNDROME; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA; LONG TERM CARE; LUNG TOXICITY; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MORTALITY; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POLYNEUROPATHY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SALVAGE THERAPY; TRANSFORMED NONHODGKIN LYMPHOMA; UPPER GASTROINTESTINAL BLEEDING; WHOLE BODY RADIATION;

ADULT; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 79551680909     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.07.007     Document Type: Article

References (36)

1. Ladetto M., De Marco F., Benedetti F., et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008, 111:4004-4013.
2. Schouten H.C., Qian W., Kvaloy S., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003, 21:3918-3927.
3. Lenz G., Dreyling M., Schiegnitz E., et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:2667-2674.
4. Gyan E., Foussard C., Bertrand P., et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 2009, 113:995-1001.
5. Montoto S., Canals C., Rohatiner A.Z., et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007, 21:2324-2331.
6. Rohatiner A.Z., Nadler L., Davies A.J., et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007, 25:2554-2559.
7. Vose J.M., Bierman P.J., Loberiza F.R., et al. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant 2008, 14:36-42.
8. Tam C.S., Khouri I.F. Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma. Leuk Lymphoma 2009, 50:1239-1248.
9. van Besien K., Loberiza F.R., Bajorunaite R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003, 102:3521-3529.
10. Bierman P.J., Sweetenham J.W., Loberiza F.R., et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation-The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003, 21:3744-3753.
11. Jones R.J., Gocke C.D., Kasamon Y.L., et al. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood 2009, 113:5920-5926.
12. Matsui W., Wang Q., Barber J.P., et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008, 68:190-197.
13. Geisler C.H., Kolstad A., Laurell A., et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112:2687-2693.
14. Williams C.D., Goldstone A.H., Pearce R.M., et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996, 14:2454-2464.
15. Fouillard L., Laporte J.P., Labopin M., et al. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation-results of a retrospective analysis on 120 patients autografted in a single institution. J Clin Oncol 1998, 16:2803-2816.
16. Emadi A., Jones R.J., Brodsky R.A. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009, 6:638-647.
17. Yeager A.M., Kaizer H., Santos G.W., et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 1986, 315:141-147.
18. Rowley S.D., Davis J.M. The use of 4HC in autologous purging. Bone Marrow Processing and Purging: A Practical Guide 1991, 248-262. CRC Press, Inc., Boca Raton, FL. 1st ed. A.P. Gee (Ed.).
19. Grochow L.B., Jones R.J., Brundrett R.B., et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989, 25:55-61.
20. Santos G.W., Tutschka P.J., Brookmeyer R., et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983, 309:1347-1353.
21. Gray R.J. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988, 16:1141-1154.
22. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. JASA 1999, 94:496-509.
23. Ihaka R., Gentleman R.R. A language for data analysis and graphics. J Comput Graph Stat 1996, 5:299-314.
24. Brown J.R., Feng Y., Gribben J.G., et al. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007, 3:1057-1065.
25. Sabloff M., Atkins H.L., Bence-Bruckler I., et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 2007, 13:956-964.
26. Kornacker M., Stumm J., Pott C., et al. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol 2009, 20:722-728.
27. Bierman P.J., Vose J.M., Anderson J.R., et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997, 15:445-450.
28. Kasamon Y.L., Jones R.J., Brodsky R.A., et al. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol 2010, 21:1203-1210.
29. Sebban C., Mounier N., Brousse N., et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006, 108:2540-2544.
30. Rohatiner A.Z., Johnson P.W., Price C.G., et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994, 12:1177-1184.
31. Bird J.M., Luger S., Mangan P., et al. 4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation in non-Hodgkin's lymphoma patients at high risk of bone marrow involvement. Bone Marrow Transplant 1996, 18:309-313.
32. Rowley S.D., Piantadosi S., Marcellus D.C., et al. Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts. Bone Marrow Transplant 1991, 7:183-191.
33. Rowley S.D., Jones R.J., Piantadosi S., et al. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia. Blood 1989, 74:501-506.
34. Gribben J.G., Neuberg D., Freedman A.S., et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993, 81:3449-3457.
35. Gribben J.G., Freedman A.S., Neuberg D., et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991, 325:1525-1533.
36. Freedman A.S., Neuberg D., Mauch P., et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999, 94:3325-3333.